Navigation Links
FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Date:3/18/2008

RARITAN, N.J., March 18 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced that it received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

J&JPRD, along with its co-development partner, Swiss-based Basilea Pharmaceutica Ltd., is reviewing the agency's letter and will work quickly to resolve any outstanding issues. The NDA for ceftobiprole was submitted to the FDA last May.

An application for the use of ceftobiprole in adults in the same indication is currently under regulatory review in Europe, Australia, Canada and in other countries.

J&JPRD is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Asia, Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and descrip
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
3. HHS Issues First Department-Wide Report on Personalized Health Care
4. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
5. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
9. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... CA (PRWEB) August 19, 2014 Robin ... Parkinson’s disease can take on an individual. Symptoms ... decreased facial expression, problems swallowing and severe depression. ... the dying off of dopamine producing neurons of the ... from a disease that slowly and progressively gets worse, ...
(Date:8/19/2014)... , Aug. 19, 2014 ... addition of the "Spectroscopy Equipment and ... report to their offering. ... Spectroscopy Equipment and Accessories in US$ Thousands ... (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical ... of post-approval use in the U.S. of XIAFLEX® for ... palpable cord.  After approximately 11,000 injections administered to approximately ... meaningful change in the nature of events expected relative ...
... 2011 Genprex, Inc., formerly known as Convergen ... nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™ ... brand in the oncology sector in recognition of our ... will be used to unlock the unrealized potential of ...
... - QIAGEN assay for JAK2 V617F mutation ... ,JAK2 inhibitor, and to monitor responses to therapy ... exclusive access to JAK2 biomarker underpins potential future expansion with ... QGEN ; Frankfurt, Prime Standard: QIA) today announced that ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 4
(Date:8/19/2014)... at San Antonio and The University of Texas at ... than $750,000 in grants through the San Antonio Life ... SALSI is a model of how a general academic ... forces for greater research and graduate education. , The ... public health issues and diseases of global impact. Funding ...
(Date:8/19/2014)... August 2014: An engineer at the University of Liverpool ... a brain to communicate with the body. , Dr ... Mahadevan, has developed a mathematical model for earthworms and ... these soft bodied animals get around. , The most ... generator (CPG) which states that the central brain of ...
(Date:8/19/2014)... study that analyzed concentrations of African dust transported ... winter and spring. These research findings offer new ... quality impacts of African dust, including the climate ... occur from increased African dust emissions in the ... (UM) Rosenstiel School of Marine and Atmospheric Science ...
Breaking Biology News(10 mins):San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3Secrets of how worms wriggle uncovered 2Study of African dust transport to South America reveals air quality impacts 2
... , The University of Haifa, Israel, has dedicated Israel,s ... focus on research and development of non-irrigated green roofs; ... and evolutionary theories. The center has been ... expert in the field, and was facilitated by VP ...
... Investigators at Washington University and The Scripps Research Institute ... to facilitate meta-analyses on studies of the metabolism of ... of the Global Metabolomic Initiative was sent to more ... a total of more than 35,000 files of metabolomic ...
... und MÜNCHEN, 7. November 2012 Bausch + Lomb, ... er seine Option zum Kauf aller im Umlauf befindlichen ... GmbH (TPV) ausgeübt hat, einem führenden Hersteller ophthalmologischer Lasersysteme. ... aus einem Joint Venture zwischen Bausch + Lomb und ...
Cached Biology News:Israel's first Green Roofs Ecology research center dedicated at University of Haifa 2Global metabolomic initiative announced 2Global metabolomic initiative announced 3Global metabolomic initiative announced 4Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 2Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 3Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 4
... a serine/threonine phosphatase isolated from human red ... heterodimer of 60kDa (A) and 36kDa (C) ... the a-subunit of phosphorylase kinase. With its ... specificity and may play a regulatory role ...
... Monitoring Kit measures adenosine triphosphate ... and a dynamic range. Based ... assay measures ATP in bacterial, ... a concentration range of 10-11 ...
... Jouan RCT series of refrigerated cold traps ... trapping of low volatility/aqueous solvents or high ... and other vacuum concentrators/centrifugal evaporators. Also used ... systems such as used in electron microscopes. ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: